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ABSTRACT
Objective Estimating survival can aid care planning, 
but the use of absolute survival projections can be 
challenging for patients and clinicians to contextualise. 
We aimed to define how heart failure and its major 
comorbidities contribute to loss of actuarially predicted 
life expectancy.
Methods We conducted an observational cohort study 
of 1794 adults with stable chronic heart failure and 
reduced left ventricular ejection fraction, recruited from 
cardiology outpatient departments of four UK hospitals. 
Data from an 11- year maximum (5- year median) follow- 
up period (999 deaths) were used to define how heart 
failure and its major comorbidities impact on survival, 
relative to an age–sex matched control UK population, 
using a relative survival framework.
Results After 10 years, mortality in the reference 
control population was 29%. In people with heart 
failure, this increased by an additional 37% (95% CI 
34% to 40%), equating to an additional 2.2 years of 
lost life or a 2.4- fold (2.2–2.5) excess loss of life. This 
excess was greater in men than women (2.4 years 
(2.2–2.7) vs 1.6 years (1.2–2.0); p<0.001). In patients 
without major comorbidity, men still experienced excess 
loss of life, while women experienced less and were 
non- significantly different from the reference population 
(1 year (0.6–1.5) vs 0.4 years (−0.3 to 1); p<0.001). 
Accrual of comorbidity was associated with substantial 
increases in excess lost life, particularly for diabetes, 
chronic kidney and lung disease.
Conclusions Comorbidity accounts for the majority of 
lost life expectancy in people with heart failure. Women, 
but not men, without comorbidity experience survival 
close to reference controls.
INTRODUCTION
Chronic heart failure (CHF) is a common late 
phase in the natural history of many cardiovascular 
diseases, affecting millions of people globally, and 
remains associated with an appreciable mortality 
rate.1 In spite of declining age–sex adjusted 
incidence rates, the prevalence of heart failure 
continues to increase,2 reflecting improving survival 
rates and an ageing population. Hence, people with 
heart failure are increasingly old and have a rising 
burden of major comorbidity.2 These trends pose 
challenges for the estimation and communication of 
prognosis, with important implications for patients 
and clinicians aiming to make well- informed deci-
sions. For example, established prognostication 
tools may be less reliable at predicting remaining 
life expectancy in people over 80 years3 and do 
not convey the substantial risk of death in similarly 
aged individuals without heart failure. Moreover, 
prognostic estimates do not describe the relative 
contribution of heart failure versus associated 
comorbidities, which may be important in defining 
therapeutic priorities in the growing population 
with multimorbidity. Indeed, non- cardiovascular 
causes of death are increasingly common in people 
with heart failure, especially with advancing age.4 5 
Furthermore, prior research has shown substantial 
discordance between patient- predicted and prog-
nostic model- predicted survival, illustrating the 
need to better communicate this important and 
sensitive topic.6 These issues suggest that alternate 
approaches to considering and communicating 
prognosis may be helpful for health professionals 
and people with heart failure. Therefore, we set out 
to describe the survival of people with heart failure 
relative to an age–sex matched control population 
and then define how comorbid disease contributes 
to the observed loss of survival.
METHODS
As described in our earlier publications,4 we 
conducted a prospective cohort study with the 
predefined aim of identifying prognostic markers 
in patients with CHF and reduced left ventricular 
ejection fraction (LVEF), receiving contemporary 
evidence- based therapy. This manuscript presents 
a post hoc analysis of the original study. Inclusion 
in the study required the presence of stable signs 
and symptoms of CHF for at least 3 months, age 
≥18 years and LVEF ≤45% on transthoracic echo-
cardiography. Between June 2006 and December 
2014, consecutive patients attending specialist 
cardiology clinics (secondary and tertiary referral) 
in four UK hospitals were approached, and 1794 
patients provided written informed consent. The 
Leeds West Research Ethics Committee gave ethical 
approval and the investigation conforms to the 
principles outlined in the Declaration of Helsinki.
Details of comorbid illness and symptomatic 
status (New York Heart Association (NYHA) classi-
fication) were collected by the recruiting physicians 
using medical history and care records at study 
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enrolment, as we have previously described.4 Briefly, diabetes 
was defined on the basis of previous diagnosis and/or treatment 
with hypoglycaemic agents; chronic obstructive pulmonary 
disease (COPD) was defined on the basis of previous diagnosis 
and ischaemic aetiology was defined on the basis of detailed 
medical history and cardiac investigations (ECG, non- invasive 
imaging and coronary angiography, as appropriate). Venous 
blood was collected at study recruitment for assessment of renal 
function in the local hospital chemical pathology laboratories. 
Estimated glomerular filtration rate (eGFR) was calculated using 
the Modification of Diet in Renal Disease method, with chronic 
kidney disease (CKD) stage 4 or worse being defined as eGFR 
<30 mL/minute/1.73 m2.7 Two- dimensional echocardiography 
was performed according to the American Society of Echocar-
diography recommendations.8 Resting heart rate was measured 
using 12- lead ECGs. Prescribed doses of loop diuretics, ACE 
inhibitors (ACEi), angiotensin receptor blockers (ARB) and 
β-adrenoceptor antagonists (β-blockers) were collected at study 
recruitment. Total daily doses of β-blockers, ACEi (or ARB if 
used instead of ACEi) and loop diuretic were expressed relative 
to the maximal licensed dose of bisoprolol, ramipril and furose-
mide, respectively, as previously published.4 Receipt of cardiac 
resynchronisation therapy or implantable cardioverter defibril-
lator was assessed during the 6- month period after recruitment.
All patients were registered with the UK Office of Population 
Censuses and Surveys, which provided details of time of death, 
with a final censorship date of 8 November 2018; maximum 
follow- up was for 11 years. Actuarial survival predictions were 
derived from the UK National Life Tables (UK- NLT), an official 
survival estimation measure produced by the UK government.9 
The UK- NLT provide annual death rates by sex and age for 
overlapping 3- year periods, which we assigned the value to the 
middle of the range: for example, the death rate for 2011–2013 
is used with patients recruited in 2012. This provides the base-
line survival for members of the public with this age and sex, 
which we used as a reference control population.
Statistics
Patient characteristics are reported using the mean and SD for 
continuous variables, with categorical variables summarised 
using the count of each class and the percentage of the dataset 
it represents. Median survival rates and Kaplan- Meier curves 
describing the observed cohort survival, stratified by sex, were 
produced using the survival package in R (https:// CRAN. R- 
project. org/ package= survival). Relative survival data were 
produced using the relsurv package within R (https://www. 
jstatsoft. org/ article/ view/ v087i08) and illustrated with both 
expected mortality (the age–sex matched mortality rate in the 
general population defined by the UK- NLT) and excess mortality 
(the mortality rate in our study cohort after removing age–sex 
matched mortality rate in the general population) curves. In 
particular, we investigated the excess loss of life associated with 
heart failure, both in the entire cohort, stratified by sex, and 
according to the number of comorbidities. Wald CIs are used for 
mortality rate, while 500 bootstrap samples are used to produce 
CIs for years of life lost, with t- tests to compare the means 
between sexes.
To investigate the independent impact of comorbidities, a 
multiplicative relative survival model was produced using the 
relsurv package within R. The presence of four major comorbid-
ities (COPD, diabetes, ischaemic aetiology, CKD grade ≥4) were 
used as independent variables, in addition to the LVEF. These 
four comorbidities were chosen as they are included in large 
validated heart failure prognostication tools (the Seattle Heart 
Failure Model (SHFM) and the Meta- analysis Global Group 
in Chronic Heart Failure score (MAGGIC),10 11 implying likely 
association with loss of life expectancy. Excess HRs (EHRs) and 
Wald CIs are reported and fitted using the maximum likelihood 
principle. The excess hazard due to heart failure is modelled as 
a constant as our sensitivity analyses revealed this did not vary 
over time.
RESULTS
As described in table 1, the study cohort had a mean age of 69.6 
years and 73% were male. The aetiology of heart failure was 
ischaemic heart disease in 59% of cases, mean LVEF was 32% 
and 31% of people had moderate to severe dyspnoea (NYHA 
classification 3 or 4). Major comorbidity was common, with 
diabetes being present in 28%, COPD in 16% and CKD grade 
≥4 in 18%. After a maximum follow- up period of 11 years 
(median 5 years), 999 (55.7%) deaths occurred. As illustrated in 
figure 1A, median survival was 6.6 years (95% CI 6.3 to 7 years). 
However, this illustrates a composite of the excess risk of death 
in this cohort plus the background risk in the general population, 
which is likely to be substantial in the context of their advanced 
age. To address this, we constructed relative survival models 
that define the expected mortality in the background popula-
tion (figure 1B), and contrast this with the observed mortality in 
our study cohort to define their excess mortality risk (figure 1B). 
After 10 years, the expected background population mortality 
rate is 28.6% (95% CI 27.8%–29.4%); in addition to this, 
our study cohort experienced an excess risk of 37% (95% CI 
33.6% to 40.5%). Expressed as years of life lost over 10 years of 
follow- up, the expected loss accounts for 1.6 (95% CI 1.54 to 
1.72) years, while the excess risk accounts for a further 2.2 (95% 
CI 1.99 to 2.41) years, resulting in a cumulative loss of 3.8 (95% 
CI 3.66 to 4.0) years. Therefore, our study cohort lost 2.4- fold 
(95% CI 2.2 to 2.5) more life than expected.





Age (years) 69.6 (12.5) 69.3 (12.1) 70.4 (13.5) 0.1
Ischaemic aetiology 
(n (%))
1064 (59.3) 835 (63.7) 229 (47.4) <0.001
Diabetes (n (%)) 504 (28.1) 384 (29.3) 120 (24.8) 0.06
COPD (n (%)) 283 (15.8) 195 (14.9) 88 (18.2) 0.09
CKD 4 or above (n (%)) 141 (7.9) 86 (6.6) 55 (11.4) 0.001
NYHA class 3/4 (n (%)) 551 (30.7) 386 (29.5) 165 (34.2) 0.06
LV ejection fraction (%) 32 (9.5) 31.7 (9.5) 32.6 (9.5) 0.08
Beta blocker use (n (%)) 1516 (84.7) 1117 (85.5) 399 (82.6) 0.14
QRS interval (ms) 123.2 (31) 125 (30.9) 118.1 (30.7) <0.001
Bisoprolol equivalent 
dose (mg/day)
3.9 (3.4) 4 (3.4) 3.5 (3.3) 0.01
ACEi or ARB use (n (%)) 1618 (90.4) 1195 (91.4) 423 (87.6) 0.014
Ramipril equivalent dose 
(mg/day)
4.9 (3.5) 5.1 (3.6) 4.3 (3.4) <0.001
MRA use (n (%)) 684 (38.2) 507 (38.8) 177 (38.8) 0.41
Furosemide equivalent 
dose (mg/day)
51 (50) 52 (52) 49 (43) 0.18
CRT (n (%)) 452 (25.2) 353 (26.9) 99 (20.5) 0.005
ICD (n (%)) 209 (11.6) 184 (14) 25 (5.2) <0.001
Continuous data displayed as mean (SD) and categorical data as n (%).
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; COPD, 
chronic obstructive pulmonary disease; CRT, cardiac resynchronisation therapy; ICD, implantable 
cardioverter defibrillator; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; NYHA, 
New York Heart Association.
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Next we explored the impact of male sex, given its established 
role as an adverse prognostic factor. As described for figure 1, 
the observed, expected and excess mortality of the cohort, 
stratified by sex, are shown in figure 2A–C. Men and women 
exhibited similar 10- year background mortality rates (27.9% 
(26.9%–28.9%) vs 30.5% (29%–32.1%)). However, excess 
10- year mortality rates were higher in men than in women 
(40.3% (36.3%–44.2%) vs 28% (21%–35.1%)). Over 10- years 
of follow- up, the background loss of life was 1.6 years in both 
men and women, but the excess risk was 2.4 (95% CI 2.2 to 2.7) 
years in men versus 1.6 (95% CI 1.2 to 2.0) years in women, 
resulting in an average cumulative loss of 4 and 3.2 years, respec-
tively. Therefore, men and women lost 2.5- fold (95% CI 2.3 to 
2.7) and twofold (95% CI 1.7 to 2.3) more life than expected, 
respectively, suggesting male sex is associated with a higher risk 
of heart failure phenotype (p<0.001).
Given the differing comorbidity profile of men and women 
(table 1), we next explored how they might contribute to 
the differential loss of expected life in these groups. As illus-
trated in figure 3, men and women with increasing numbers of 
comorbidities experienced substantially greater loss of life expec-
tancy. Indeed, in patients with three or more comorbidities, men 
lost an excess of 4.6 years (95% CI 3.1 to 5.5), while women lost 
an excess of 3.1 years (95% CI 1.9 to 4). Importantly, in patients 
without major comorbidity, men still experienced excess loss of 
life, while women experienced less and were non- significantly 
different from the reference population (1 year (95% CI 0.6 to 
1.5) vs 0.4 years (95% CI −0.3 to 1); p<0.001). To explore the 
contribution of specific comorbidities to loss of expected life, a 
multiplicative relative survival analysis was performed and the 
EHRs are presented in table 2. All these were associated with loss 
of expected life, but with substantial heterogeneity in their effect 
size. Higher LVEF was also associated with modest reductions 
in loss of expected life. Notably, while statistically significant, 
the baseline EHR was just above 1 and approximately constant 
for the duration of the study; this implies that the excess risk 
associated with heart failure per se remained broadly constant. 
Moreover, sensitivity analyses using various approaches to allow 
time variance in the baseline excess hazard did not reveal differ-
ences in the EHRs of the main comorbidities.
Figure 1 Absolute and relative survival of the study cohort. (A) Kaplan- Meier curve illustrating observed mortality in the study cohort; (B) expected 
mortality rate (dashed line) and excess mortality rate (continuous line with shaded 95% CI) in an age- sex matched UK population.
Figure 2 Absolute and relative survival stratified by gender. (A) Kaplan- Meier curve illustrating observed mortality of men and women in the study 
cohort; (B) expected mortality rate in an age- matched UK populations of men and women; (C) excess mortality rate in men and women from the 
study cohort relative to the age–sex matched UK populations, illustrating greater excess mortality in men than women with heart failure.
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DISCUSSION
By considering survival relative to actuarial estimates of life 
expectancy, we have shown that heart failure is associated with 
a 2.4- fold greater loss of time alive than observed in the age–sex 
matched general population over 10 years. Notably, male sex 
and accrual of major comorbidities are associated with larger 
loss of life, while women without major comorbidity have life 
expectancy compatible with actuarial projections. Lower LVEF 
was also associated with greater excess loss of life. This approach 
to defining survival may provide useful perspective for clinicians 
considering the magnitude of risk posed by heart failure in the 
context of an ageing and increasingly multimorbid population. 
This context may be particularly useful when communicating 
risk to people with heart failure, who often struggle to estimate 
their own prognosis.
Estimating prognosis
Validated tools, such as SHFM and MAGGIC,10 11 are already 
available to estimate the prognosis of people with heart failure 
in terms of absolute lifespan. While valuable, it is important 
to ask whether this approach tells patients and clinicians what 
they want to know. By overlooking the inevitability of death in 
similar people without disease, such prognostic estimates may be 
misinterpreted, resulting in poorly informed decision- making. 
The challenges of prognostication in people with heart failure 
are illustrated by the discordance between model- estimated 
and patient- estimated absolute life expectancy.6 By considering 
survival relative to actuarially predicted life expectancy, we hope 
that our approach will provide essential context to aid the chal-
lenging process of communicating prognosis. This may take the 
form of ‘ballpark’ estimates of excess loss of life for groups of 
similar people or by developing an individualised prognostication 
tool, such as the SHFM. Further research is needed to address 
the validity, acceptability and added value of this approach, but 
we think that it has the potential to improve prognostication in 
clinical practice.
Multimorbidity as risk marker and therapeutic target
Recent research describing all people with heart failure in a 
representative cohort of 4 million UK residents found that multi-
morbidity is becoming increasingly common.2 While we focused 
on just four major comorbidities, 26% of our cohort were not 
multimorbid (ie, heart failure with at least one comorbidity), 
and 31% had two or more of these comorbidities. Strikingly, 
people with three or more comorbidities experienced approx-
imately fivefold greater excess loss of life than people with no 
comorbidity (figure 3). While we selected comorbidities known 
to contribute to prognostication in people with heart failure, this 
confirms that the accumulation of comorbidity is an important 
part of lost life expectancy in heart failure; it will be important 
for further research to study the additional impact of other 
common comorbidities. Optimal medical therapy is associ-
ated with substantial reductions in heart failure morbidity and 
lifespan extension in clinical trial participants,12 yet clinical trials 
often exclude multimorbid people. These data highlight the need 
to design clinical trials specifically recruiting people with heart 
failure and multimorbidity, possibly applying complex interven-
tions that target more than just the heart failure syndrome.
Heart failure in men and women
Poorer survival of men has been observed in many studies of 
heart failure and is accounted for in the SHFM and MAGGIC 
prognostic models.10 11 While this could to some extent be 
attributed to differences in comorbidity, such as ischaemic heart 
disease, our observations from people with heart failure and no 
major comorbidity still show clear differences in the outcomes of 
men and women. Notably, the survival of women without major 
comorbidity overlapped with that of the matched general popu-
lation (figure 3). The mechanisms of this sexual dimorphism 
remain debated,13 14 but it is clear that clinical trials and guide-
lines should carefully consider the differences between men and 
women with heart failure.
Limitations
Although our work has key strengths, it is important to acknowl-
edge limitations that should be addressed by ongoing research. 
First, we have deliberately chosen not to derive an individual-
ised risk assessment tool; however, our methods could easily 
be used to extend the data provided by individualised prog-
nostic models, such as SHFM and MAGGIC.10 11 It will also 
be important to understand whether healthcare professionals 
and patients find survival estimates relative to actuarial life 
Figure 3 Loss of expected life according to sex and number of 
comorbidities. Loss of expected life over 10 years of follow- up, with 95% 
CI, in men (red) and women (blue) according to number of comorbidities 
(from ischaemic heart disease, chronic obstructive lung disease, diabetes 
and chronic kidney disease stage 4 or above).
Table 2 Multivariate survival analysis
EHR
95% CI of EHR
P valueLow High
Diabetes 1.61 1.40 1.84 <0.001
COPD 1.79 1.53 2.09 <0.001
Ischaemic aetiology 1.06 0.93 1.22 0.386
CKD 4 or above 1.62 1.33 1.99 <0.001
LVEF (per % increase) 0.98 0.97 0.98 <0.001
Baseline 1.00 1.00 1.00 <0.001
Excess HRs describe risk of reduced life expectancy relative to actuarial projections.
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; EHR, 
excess HR; LVEF, left ventricular ejection fraction.
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expectancy more useful than absolute survival estimates. Next, 
our data should not be generalised to other populations (eg, 
heart failure with preserved ejection fraction or patients not 
attending specialist heart failure clinics), but our methods could 
easily be applied to published datasets. It is also important that 
our 11- year follow- up period represents a modest proportion 
of predicted life expectancy in our youngest participants, and 
our cohort is relatively old, so caution should be applied in 
extrapolating our data to the youngest people with heart failure. 
Moreover, we were unable to account for the likely accrual of 
comorbidity over time, which may have led to underestimation 
of their association with excess mortality. Finally, it is important 
to note that our expected survival data are derived from the UK 
general population which will include some people with heart 
failure; therefore, loss of expected survival is in relation to the 
age–sex matched general population, not an age–sex matched 
heart failure free population.
CONCLUSIONS
By framing survival in the context of actuarial predictions, we 
have shown that people with heart failure with reduced LVEF 
lose 2.4- fold more of life than expected. However, most of this 
loss of life expectancy is accounted for people with comorbidity, 
particularly in women. Our work provides a different frame-
work for clinicians and people with heart failure to consider 
prognosis and should prompt more focus on the issue of heart 
failure associated with complex multimorbidity.
Key questions
What is already known on this subject?
 ► Heart failure is associated with high mortality rates and 
estimates of prognosis often inform treatment decisions. 
However, survival estimates rarely consider what would be 
expected in a person of a similar age and sex without heart 
failure and so may be largely influenced by these factors, 
rather than heart failure and its comorbidities.
What might this study add?
 ► We defined the survival of people with heart failure relative 
to the age–sex matched UK population and show a marked 
increase in lost life expectancy as comorbidity accrues. 
Women, but not men, without comorbidity experienced 
survival close to the age–sex matched reference population.
How might this impact on clinical practice?
 ► Estimates of prognosis in people with heart failure should 
also consider what would be expected in the age–sex 
matched general population to focus on the disease- specific 
risks. Future clinical trials focused on improving survival in 
people with heart failure should focus on multimorbidity, 
possibly applying complex interventions that target more 
than just the heart failure syndrome.
Twitter Michael Drozd @DrMikeDrozd, Samuel D Relton @sdrelton, Thomas A 
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